Lataa...
SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease
Castration-resistant prostate cancer (CRPC) remains a lethal disease despite the introduction of second generation androgen receptor (AR) directed therapies. Resistance to AR directed therapies, such as abiraterone and enzalutamide, emerges through diverse alterations in the AR pathway or transition...
Tallennettuna:
| Julkaisussa: | J Endocr Soc |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Endocrine Society
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551945/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-330 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|